PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders

Latest News Updates

18th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 4th May 2023 (Educational supporters)

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon

Posted on 5 July 2023 | Posted by Alberto Zambon | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board

Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Erik Stroes

Posted on 21 June 2023 | Posted by Erik Stroes | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board

Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Benoit Arsenault

Posted on 21 June 2023 | Posted by Benoit Arsenault | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board

Lp(a) and plaque progression: Insights from imaging

Lp(a) and plaque progression: Insights from imaging

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Marc Dweck

Posted on 8 June 2023 | Posted by Marc Dweck | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board

LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Stephen Nicholls

Posted on 8 June 2023 | Posted by Steve Nicholls | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved